

References

- Abdel-Aziz F., Habib M. and Mohamed M.K. (2000):** "Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence". *Hepatol.J*; 32: 111-115.
- Abo Al-Azm A and El-Sheikh M (1996):** prevalence of hepatitis C and B viruses in Gharbia Governorate rural area in comparison with a group of blood donors. *JHGID*; 4(4): 31-39.
- Adinolfi LE, Giordano MG, Andreana A, et al(2001) :** Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. *Br J Haematol* 2001; 113: 590-5.
- Akiko Yamane, Takanori Nakamura and Hidenori Suzuki et al(2008);**Interferon-2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes *Blood*, 1 August 2008, Vol. 112, No. 3, pp. 542-550.
- Alberti, A. and Bersvegnu, L. (2003):** Management of hepatitis C. *Journal of Hepatology*; 38: S104-S118.
- Alberti, A.; Chemello, L. and Bonetti, P.(1993):**Therapy of acute hepatitis C. *Hepatology*; 36 (5 Suppl.1); S195-S200.
- Alter H, Jett B, Polito A, et al., (1991):** Analysis of the role of hepatitis C in transfusion-associated hepatitis. In: Hollinger F, Lemon S, Margolis H (eds): *Viral Hepatitis and Liver Disease*. Baltimore, Williams & Wilkins:396-402.

Alter H.J., peck N. and Seeff L.B. (2002): "Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome". *Seminars in liver Dis*; 20(1): 17-35. *Am. J. Med.*, 107(6B): 2S-9S.

Angelico, M.; Ringanohem, E. and Gandian, C. (1997): Chronic liver disease in the Alexandria governate, Egyptian: contribution of schistosomiasis and hepatitis virus infections. *J. Hepatol.*, 26(2) 236-243.

Armstrong GL, Aler MJ, Mcguillan GM, et al, (2000): The past incidence of hepatitis C virus uinfection. *Hepatology*, 31:777-782.

Arnold SM, Lowy AM, Patchell Rand Foon KA(2001): paraneoplastic syndromes. *Cancer: principles and practice of oncology* 2001 ; 6th ed.: 2517-8.

Arthur MJ (2004): Degradation of matrix proteins in liver fibrosis. *Path. Res. Praact.*; 190:825-832.

Attili, A.F.; Rusticali, A. and Varriale, M. (1994): The effect of ursodeoxycholic acid ov serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial.

Bach, E.A: Aguet, M. and Schreiber, R.D.(1997): The IFN gamma recertor: a paradiagm for cytokine receptor signaling. *Annu. Rev. Immunol.*, 15:563-591.

Bacon, B.R.(2002): Treatment of patients with hepatitis with hepatitis C and normal serum aminotransferase levels. *Hepatology*; 36(5 Suppl.1):S179-S184.

Baglioni, C: Maroney, P.A. AND West,D.K.(1979). 1,5 oligo (A) polymerase activity and inhibition of viral RNA synthesis in interferon treated Hela cells. Biochemistry, 18:1765-1770.

Bailon, p.: Schafer, C.A. and Spence, C. (1996): Long lasting forms of poly ethylene glycol conjugated interferon- α 2a. Roche Research Report N-130915,May 3,1996.

Bain V.G.; Bonacini M.; Govindarajan S.; Sherman M. et al., (2004):Role of liver biopsy in assessment of patients with chronic hepatitis C. J. Viral hepatitis 11(4): 375-382.

Balaguer F, Fernandez J, Lozano M, et al(2005): Cocaine-induced acute hepatitis and thrombotic microangiopathy. JAMA 2005;293(7):797-8.

Baldwin PD(2003): Thrombocytopenia Clin J Oncol Nursing 2003;7:349-52.

Ballard HS(1989): Hematological complications of alcoholism. Alcohol Clin Exp Res 1989;13: 706-20.

Banks RE(2000): Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls. Cri Reviews in Clinical Lab Sci 2000; 37: 131-82.

Bartenschlager, R. and V. Lohmann (2000): Replication of HCV. J. Gen. virol 81: 1631 – 1648.

Bashour FN, Teran JC and Mullen KD(2000): prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9.

Bass, B.L.(1997): RNA editing and hypermutation by adenosine deamination. Trends Bio. Chem. Sci., 22:157-162.

Berg, T; Kronenberger, B.; Hinrichsen,H.; et al.(2003): Triple therapy with amantadine in treatment naïve patients with chronic hepatitis C: A placebo-controlled trial. *Hepatology*, 37(6): 1359-1367.

Bhatt DL and Topol EJ(2003): Scientific and therapeutic advances in anti-platelet therapy. *Nature Drug Discovery* 2003; 2:15-8.

Biasin, C.A. and Sen, G.C.(2001): Interferons and other cytokines p. In D.M Knipe, p.m. Howley, D.E Griffin, M. Martin, B. Roziman and S.E. Strans (ed.), *Fields Virology*, 4th ed. Lippincott-Raven, Philadelphia, Pa. 321-351.

Blair, R. C. (1981). "A reaction to 'Consequences of failure to meet assumptions underlying the fixed effects analysis of variance and covariance.'" *Review of Educational Research*, 51, 499-507.

Boehm, U.; Klamp, T.; Groot, M. and Howard, J.G. (1997): Cellular responses to interferon gamma. *Annu. Rev. Immunol.*, 15:749-795.

Booth, J.; Foster, G. and Kumar, U.(1995): Chronic hepatitis C virus infections predictive value of genotype and level of viraemia on disease progression and response to interferon. *Gut*; 36:427-32.

Booth, J.C.L.; O'Grady, J. and Neuberger, J.(2001): Clinical guidelines on the management of hepatitis C. *Gut*; 49(Suppl. I): 11-121.

Bordin G, Ballaré M, Zigrossi P, et al(1995). A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? *Clin Exp Rheumatol* 1995;13:Suppl 13:S39-S43.

Borrow P, Wei X, Howitz MS, et al., (1997): Antiviral pressure exerted by HIV-1 specific CTLs during primary infection

demonstrated by rapid selection of CTL escape virus Nat. Med., 3:212-217.

Braet F, Shleper M, et al(2004) : Liver sinusoidal endothelial cell modulation upon resection and shear stress in vitro. Comp Hepatol 2004;3:7.

Bressler BL, Guindi M, Tomlinson G. et al.(2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-44.

Brunt E.M. (2000): "Nonalcoholic steatohepatitis: definition and pathology". Semin. Liver Dis.; 21:3-16.

Cairns J, Kennedy JW and Fuster V(1998) : Caronary Thrombolysis. Chest 1998;114(5):634-57.

Campbell M. and Reddy K. (2004): "The Evolving Role of Liver Biopsy" Aliment Pharmacol Ther.; 20(3):249-259.

Cantin, E.; Tanamachi, B.; Openshaw, H.; Jmann and Clarke, K. (1999): Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type I infection than IFN gamma ligand null-mutat mice. J. Virol., 73;5196-5200.

Causse, X.; Godinot, H. and Chevallier, M. (19991): Comparison of 1 or 3 Mu of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. gastroenterology; 1 c1: 497-502.

Centers for Disease control and prevention (1998): Recommendation for prevention and control of HCV infection and HCV- related chronic disease. Morb. Mortal. Wkly. Rep. 47. (RR – 19): 1–39.

Chang KM, Rehermann B, McHutcheon, et al., (1997):

Immunological significance of CTL epitope variants in patients chronically infected with HCV. J. Clin. Invest., 100: 2376-2385.

Chen, M.; Sonnerborg, A. and Sallberg, M. (1995): Levels of HCV RNA in serum and their relationship to level of immunoglobulin M and G antibodies against HCV core protein. J. Clin. Microbiol. 33,778–780.

Cheng, S.J.; Bonis, P.A.L.; Lau, J.; Pharm, N.Q. and Wong, J.B.(2001): Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a metaanalysis of controlled and uncontrolled trials. Hepatology; 33:231-240.

Chong-Shan Wang,1,2 Wei-Jen Yao,3 Shan-Tair Wang,et al(2004):-
: Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: Implications from a Survey of a Community with Hyperendemic HCV Infection: Clinical Infectious Diseases 2004;39:790-796.

Choo QL, Kuo G, Ralston R, et al. (1994): Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. Usa; 91:1294-8.

Choo, Q.L.; G. Kuo; A.J. Weiner; L. R. Overby; M. Houghton (1989): Isolation of a cDNA Clone derived from a blood-borne non- A, non- B viral hepatitis genome. Science 244: 359 – 362.

Choo, Q.L.; K. H. Richman; J.H. Han; K. Berger et al. (1991):Genetic organization and diversity of the HCV. Proc. Natl. Acad. Sci. USA. 88: 2451–2455.

Ciesla B(2007) : Hemostasis and Disorders of Coagulation. Hematol In Prac 2007; VOL IV:233.

Cines DB(2000): Approach to the patient with thrombocytopenic
Kelley's textbook of internal medicine 2000;4th ed; 1733-40.

Clavien PA(2008): Liver regeneration: a spotlight on the novel role of platelets and serotonin. Swiss Med Wkly 2008; 138:361-70.
contribution of schistosomiasis and hepatitis virus infections.

Dai CY, Ho CK, Huang JF, et al(2010). Hepatitis C virus and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol 2010;52:160-166.

Dal Molin, G.; D' Agaro, P.; Ansaldi, F., et al., (2002)-a: Mother-to- infant transmission of HCV. Rate of infection and assessment of viral load and IgM anti – HCV as risk Factors. J Med. Virol. 67: 137 -142.

Darke WT, Lopes MN, Fenton JW and Sekutz AC(1992):
Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest 1992;67:617.

Darnell, J.E.Jr.(1997): STATs and gene regulation.Science, 277:1630-1635.

Darnell, J.E.Jr.; Kerr, I.M. and Stark, G.M.(1994): Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264:1415-1421.

Davies PS, Day JM, Cole TJ(1993).: Converting Tanner-Whitehouse reference tricep and subscapular skinfold measurements to standard deviation scores. Eur J Clin Nutr. 1993 Aug;47(8):559-66.

Davis, G. and Lau, J. (1997): Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology; 26(Suppl. 1):122-7S.

Davis, G.L.(2002): Monitoring of viral levels during therapy of hepatitis C. Hepatology; 36((5 Suppl. 1);S145-51.

De Maria, N.; A. Colantonia; R. Idilman; L. Friedlender; J. Harig (2002): Impaired response to high dose interferon treatment in African–Americans with chronic hepatitis C. Hepatogastroenterology 49: 788–792.

Dennis M. Miller¹, Kevin M. Klucher¹, Jeremy A. Freeman¹, et al (2009):- Interferon Lambda as a Potential New Therapeutic for Hepatitis C, annal of the new York academy of science. Article first published online: 10 DEC 2009.

Desser, L. and Rehberger, A. (1990): Induction of tumor necrosis factor in human peripheral blood mononuclear cells by proteolytic enzymes. Oncology; 47:474-477.

Diana V Stefanova-Petrova, Anelia H Tzvetanska, Elisaveta J et al(2007): Chronic hepatitis C virus infection: Prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients: R World J Gastroenterol 2007 December 28;13(48): 6518-6528.

DiBisceglie, A.M. and Hoofnagle, J.H.(2002): Optimal therapy of hepatitis C. Hepatology; 36(5 Suppl. 1): S121-127.

Dienstage JL and MeHutchison JG(2006): American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterol* 2006; 130:213-64.

Doi T, Homma H, Mezawa S, et al(2002): Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. *Hepatol Res* 2002; 24:23-33.

Dormann H, Krebs S, Muth-Selbach U, et al(2000). Rapid onset of hematotoxic effects after interferon alpha in hepatitis C. *J Hepatol.* 2000;32:1041–1042.

Dourakis SP, Deutsch M, Hadziyannis SJ(1996). Immune thrombocytopenia and alpha interferon. *J Hepatol* 1996; 25:972-975.

Drews RE: Critical issues in hematology (2003): Anemia, thrombocytopenia, coagulopathy, and blood product transfusion in critically ill patients. *Clin Chest Med* 2003; 24(4):604-22.

Dsheiko, G. (1997): Side effects of alpha interferon in chronic hepatitis C. *Hepatology*; 26 (Supl. 1):12 S-21S.

EASL International Conference on Hepatitis C (1999): Paris, 26-28 February 1999, Consensus Statement. *J. Hepatol.*, 30:957-61.

El-Zayadi A, Abaza H, Shawky S and et al., (2001): Prevalence and epidemiological features of hepatocellular carcinoma in Egypt- a single center experience. *Hepatology Research* ; 19: 170-179.

El-Zayadi A., Simmonds A. and Dabbous H. (1996): "Response to interferon- α of Egyptian patients infected with hepatitis C virus genotype 4". *J. Viral Hepatitis*; 3:261-264.

Escolar G, Cases A, Vinas M, et al(1999): Evaluation of acquired platelet -dysfunction analyzer (PFA 100 TM): Influence of hematocrit elevation. Haematol 1999;84:614-9.

Fagerland, M.W., and L. Sandvik.(2009). The Wilcoxon-Mann-Whitney test under scrutiny. Statist. Med. 28: 1487-1497.

Ferrero S., Lungaro P., Bruzzone B.M. and Gotta C. (2003): "Prospective study of mother-to-infant transmission of hepatitis C virus: a ten year survey (1990-2000)". Acta. Obstet. Gynecol. Scand; 82: 229-234.

Fiorentino DF, Ziotnik A, Viera P et al., (1991): IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 146:3444.

Flamm S.L., Parker R.A. and Chopra S. (1998): "Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission". Am. J. Gastroenterol.; 93: 597-600.

Forns, X and Bukh, J. (1999): The molecular biology of HCV: Genotypes and Quasispecies. Clinics in liver disease 3 (4), 1999.

Francesca J. Torriani, M.D., Maribel Rodriguez-Torres et al.(2004),:- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients, The New England Journal of Medicine: 2004- Volume 351:438-450.

Frank C, Mohamed MK, Strickland GT, et al., (2000): The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet; 355:887-891.

Friebe, P. and R. Bartenschlager (2002): Genetic analysis of sequences in the 3' nontranslated region of HCV that are important for RNA replication. J. Virol. 76: 5326 – 5338.

Fried, M.W.; Shiffman, M.L.; Readdy, R.; et al. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347:975-982.

Friedman LS(2004): Controversies in liver biopsy: Who, where, when. How.why? Curr Gastroenterol Rep 2004;6:306.

Friedman S. and Keefe B. (2004): "Cirrhosis and portal hypertension" In Friedman S, Keefe B. "Hand Book of Liver disease"; p125-132.

G Shiota, M Okubo, H Kawasaki, et al (1997) Interferon increases serum thrombopoietin in patients with chronic hepatitis C. Br J Haematol. 1997 May ;97 (2):340-2.

Ganser A, Carlo-stella C, Greher J, Volkers Band Hoelzer D(1987): Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987;70:1173-9.

George JN and Veseley SK(2000): Immune thrombocytopenic purpura: Let the treatment fit the patient. New Engl J Med 2003;394:903-5. George JN: platelets. Lancet 2000;355:1531-9.

Gergely, A.E.; Lafarge, P.; Fouchard-Hubert, I. et al .(2002): Treatment of ribavirin/interferon induced anemia with erythropoietin in patients with hepatitis C. Hepatology; 1281-1282.

Giannini E, Borro P, Botta F, et al(2002). Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37: 572-577

Giannini EG(2006). Thrombocytopenia in chronic liver disease and pharmacologic treatment options. *Alimentary Pharmacology & Therapeutics* 2006;23:1055-1065.

Giannini EG, Botta F, Borro P, et al(2005) : Application of the platelet count/ spleen diameter ratio to rule out the presence of oesophageal -varices in patients with cirrhosis: A validation study based on follow-up.*Dig Liver Dis* 2005;37:779-85.

Gordon SC, Fang JW, Silverman AL, et al. (2000): The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. *Hepatology*; 32: 400–407

Grace MJ, Cutler D(2004). Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. *Antivir Chem Chemother* 15: 287-297, 2004.

Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW(1994). Thrombocytopenia in c-mpl-deficient mice. *Science*. 1994;265:1445–1447.

Hahn J.A. (2007): "Sex, drugs and Hepatitis C virus". *J. Infect. Dis.*; 195: 1556-9.

HeIM, m.h. (1999): The Jak-STAT Pathway: cytokine signaling from the receptor to the nucleus. *J.Receptor Signal transduction Res.*, 19:25-120.

Hellstrom, U.B.; Sylvon, S.P.E.; Decker, R.H. et al., (1993): Immunoglobulin M reactivity towards the immunologically active region P 75 of the core prate in of HCV in chronic HCV infection *J. Med. Viral* 39: 325–332.

Herrnstein, R. J.; Loveland, D. H.; Cable, C. (1976). "Natural concepts in pigeons". Journal of Experimental Psychology: Animal Behavior Processes 2: 285–302. doi:10.1037/0097-7403.2.4.285.

Hinrichsen, H. (2002):First report on the antiviral efficacy of BILN 2061, a novel oral HCV Serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology: 36:379A.

Histological classification and quantitation of the severity of chronic hepatitis: keep it simple in: Rothschild MA, Thung SN. Semin. Liv. Dis. 15: 414–421.

Hofmann W., Kronenberg J., Stamm E., et al. (2008):

"prospective study of BMD and metabolism in patients with chronic HCV during pegylated interferon alpha" J. viral hepat.; 15(11):790-796.

Homocik M, Ferlitsch A, Ferenci P, et al (2005): Short- and long-term effects of therapy with interferon alpha/ ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 21:49-55.

Hood JD and Cheresch DA (2002): Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2:91-100.

Hoofnagle JH (1991). Thrombocytopenia during interferon alpha therapy. JAMA 266: 849, 1991

Hoofnagle, J.H. (1997): Hepatitis C. The clinical spectrum of disease. Hepatology 1997; 26 (Suppl. 1): 15S-20S.

Hou M, Andersson PO, Stockelberg D, et al (1998); Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol 1998; 101:420-4.

Hutchison JG, Dusheiko G, Shiffman ML, et al(2007).

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med.* 2007;357:2227–2236.

Hytiroglou, P.; Thung, N.S.; Gerber, M.A. (1995):

Histological classification and quantitation of the severity of chronic hepatitis: keep it simple in: Rothschild MA, Thung SN. *Semin. Liv. Dis.* 15: 414–421.

Iga D, Tomimatsu M, ENDO h and Yamada O et al(2005):

Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon- α therapy: possible etiology of HCV-associated immune thrombocytopenia. *Eur J Haematol* 2005;75:417-23.

Isaacs, B.L. and Lindenmann, J. (1957): Virus interference. I. The interferon. *Proc. R. Soc. London Ser.* 147:258-267. Quoted from Liang and Hoofnagle (2000).

Ishak, K.; Baptista, a.; Bianchi, L.; Callea, F.; Gudat, F. et al., (1995): Histological grading and staging of chronic hepatitis. *J. Hepatol*; 22: 696–699.

Italiano JE and Shivdasani RA: Megakaryocytes and beyond(2003): the birth of platelets. *J THROMB Haemost* 2003;1:1174-82.

Ito K, Shiraki K, Sakai T, Yoshimura H and Nakano T(2005):

portal hypertensive colopathy in patients with liver cirrhosis. *World J Gastroenterol* 2005;11:3127-30.

Jacobson, B.L. and Langland, J.O.(1996): When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. *Virology*, 125:496-501.

Jandi JH(1996): physiology of red cells, in Blood: Textbook of Hematology, 2nd ed., Little, Brown, Boston, 1996, chap.3.

Jármay K, Karácsony G, Ozsvár Z, et al (1998): Histological evaluation of the response to interferon-alpha therapy in chronic hepatitis C.Scand J Gastroenterol Suppl. 1998;228:56-61.

Jean Marc Durand, MD; Gilles Kaplanski, MD; and Jacques Soubeyrand, MD(1996):- Extrahepatic Manifestations of Hepatitis C Virus Infection.1996;125 :345-7.

Jelkmann W(2001): The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gasrtoenterol Hepatol 2001;13:791-801.

John G. McHutchison, M.D., Eric J. Lawitz, M.D.,et al(2009) Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection:N Engl J Med 2009; 361:580-593.

Jun Hayashi, MD, PhD; Yasuhiro Kishihara, et al (1998) :Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection : Arch Intern Med. 1998;158:177-181

Kabil, S.M.; Salwa, M. Youssef; Atta, M.M.E et al (1996): High prevalence of hepatitis C virus RNA in saliva of patients with chronic HCV infection. Journal of Hepatology, Gastroenterology and Infectious Diseases. JHGD. Vol. 4, No. 2,pp. 1-6.

Kanai, K.; Kako, M. and Okamoto, H. (1992): HCV genotypes in chronic hepatitis C and response to interferon. Lancet; 339:1543.

Kaneko T, Moiyama T, Udaka K, et al., (1997): Impaired induction by CTLs by antagonism of a weak agonist borne by a variant HCV epitope. Eur. J. Immunol; 27:1782-1787.

Kantzanou, M.; M. Lucas; E. Bornes; H. Komatsu et al., (2003): Viral escape and T. cell exhaustion in hepatitis C virus infection analyzed using class I peptide tetramers. Immunol .Lett. 85: 165 -171.

Karmochkine M., Carrat F. and Santos D.O., et al . (2006): "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". J. Viral Hepat.; 13(11): 775-82.

Karupiah, G.; Xie, Q.W.; Buller, R.M.; Nathan, C.; Duarte, C. and MacMickin, J.D. (1993): Inhibition of viral replication by interferon gamma induced nitric, 26:1445-1448.

Kaushansky K(1998):Thrombopoietin. N Engl J Med 1998;339:746-54.

Kaushansky K, Broudy VC, Lin N, et al(1995).

Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234–3238.

Kita H, Moriyama T, Kaneko T et al., (1995): A helper T-cell antigen knockout mice: reexamination of GD1a immunolocalization.

Koike M, Sekigawa I, Ogawa K, Iida N, Oshimi K (2003) Ursodeoxycholic acid treatment of idiopathic thrombocytopenic purpura with liver dysfunction. Eur J Haematol 71: 391-392.

Kolykhalov, A.A.; Mihalik, K.; Feinstons,et al (2000): HCV encoded enzymatic activities and conserved RNA elements in the 3 non translated region are essential for virus replication in vivo . J. Virol 74: 4046 – 2051.

Koshy, A.; J.P. Madda; P. Marcellin; M. Martinot (2002):

Treatment of hepatitis C virus genotype- 4 related cirrhosis. J. Clin. Gastroenterol 35: 82 -85.

Koziel MJ, Dudley D, Afdhal N, et al., (1993):Hepatitis C virus (HCV)-specific cytotoxic T-lymphocyte recognize epitopes in the core and envelope proteins of HCV.J. Virol 7: 7522.

Kreft A, Nolde C, Büsche G, Buhr T, Kreipe H, Georgii A(2000).

Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur Haematol. 2000;64:32–41.

Kruskal and Wallis(1952). Use of ranks in one-criterion variance analysis. Journal of the American Statistical Association 47 (260): 583–621, December 1952.

Kuter DJ(2007). New thrombopoietic growth factors. Blood. 2007;109:4607–4616.

Lange RA and Hillis LD(2005): Concurrent antiplatelet and fibrinolytic therapy. New Engl J Med 2005;352:1248-50.

Large MK, Kittlesen DJ and Hahn YS (1999): Supression of host immune response by the core protein of HCV: Possible implication of HCV persistence. J. Immunol., Vol. 162:931-938.

Lau, J.Y.N.; Davis, G.L. and Kniffen, J. (1993): Significance of serum hepatitis C virus RNA levels in Chronic hepatitis C. Lancet; 341:1501-4.

Lauer, G.M. and B.D. Walker (2001): Hepatitis C Virus infection. Review article. N. Engl . J. Med. 345: 41 – 52.

Lavanchy D. (1999): "Global surveillance and control of hepatitis C".
J. Viral Hepat.; 6: 35-47.

Layden, J.E. and Layden, T.J. (2001): How can mathematics help us
understand HCV? Gastroenterology; 120:1546-1549.

Lengyel, P. (1993): Tumor suppressor genes: news about the
interferon connection. Proc. Natl. Acad. Sci. USA; 90:5895.

Lesniewski, R.; Okasinski, G.; Vansont, C. et al., (1995): Antibody
to HCV- E2 glycoprotein: a new marker of HCV infection
closely associated with viraemia. J. Med. Virol. 45: 415–422.

Li J, Yang C, Xia Y, et al (2001). Thrombocytopenia caused by
the development of antibodies to thrombopoietin. Blood.
2001;98:3241–3248.

Lin CH, Shih FY, Ma MH, Chiang WC, Yang CW and Ko PC:
Should bleeding tendency deter abdominal paracentesis? Dig Liver
Dis 2005;37:946-51.

Lindsay, K.L. (1997): Therapy of hepatitis C; overview.
Hepatology; 26(Suppl.1):715-75.

**Lisker-Melman, M.; DiBisceglie, A.M.; Uslu, S.J.; Weintraub, et al
(1992):** Development of thyroid disease during therapy of chronic viral
hepatitis with interferon alfa. Gastroenterology; 102:2155-60.

Lisman T, Bongers TN, Adelmeijer J, et al (2006): Elevated levels
of von Willebrand factor in cirrhosis support platelet adhesion despite
reduced functional capacity. Hepatol 2006;44:53-61.

Louie KS, Micallef JM, Pimenta JM, et al (2010). Prevalence of
thrombocytopenia among chronic hepatitis C patients: a systematic
review. J Viral Hepat 2010 Aug 25. [Epub ahead of print

Ludewig B, Ehl S, Karrer U, et al., (1998): Dendritic cells efficiently induce protective antiviral immunity. J. virol. 72:3812-18.

Lurie, Y; Dusheiko, G. and Rouzier-pains, R. and Glue, P(2000): Assessment of optimal dosing frequency of pegylated interferon alfa-2b (peg intorn) in chronic hepatitis C. Hepatology; 32:444A.

Mangia, A; Santoro, R; Pittelli, M; et al .(2002): High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis J. Hepatol, 37(1):109-16

Manns, M.P.; Mchutchinson, J.C.; Gordon, S. et al.(2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomized trial. Lancet; 358:958-965.

Manns, M.R; Cornberg, M and Wedemeyer, H. (2001): Current and future treatment of hepatitis C. Indian. J. Gastroenterol., 20 Suppl.1: C47-51.

Marie, I; Durbin, J.E. and Levy, D.E.(1998): Differential viral induction of distinct interferon alpha genes by positive feedback through interferon regulatory factor 7. EMBO J. 17:6660-6669.

Marinos G, Rustgi VK.(2001) Safety of interferon/ribavirin therapy in patients with thrombocytopenia using Recombinant Human IL-11 (Abstract 639). Hepatology 34, 332A. 2001.

Matsuo R, Ohkohchi N, Murata S, et al(2008): platelets Strongly Induce Hepatocyte proliferation with IGF-1 and HGF In Vitro. J Surg Res 2008;145:279-86.

McCormick PA and Murphy KM(2000): Splenomegaly, hypersplenism coagulation abnormalities in liver disease. Baillie re 's Clin Gastroenterol 2000; 14:1009-31.

McCromiak, King, I.J. and Web, A.A. (1986): Lassa fever effective tgerapy with ribavirin. N.Engl.J.Med.,413:20-26.

McHutchinson, J.G.and poynard (1999): The impact of race on response to anti-viral therapy in patients with chronic hepatitis C. Hepatology;30:302 A.

McHutchison, J.G.; T. Poynard; S. Pionko; S.C. Gordon et al., (2000): The impact of interferon plus ribavarin on response to therapy in black patients with chronic hepatitis C. The international hepatitis interventional therapy group. Gastroentrology 119: 1317 – 1323.

McMurray, R.W.(1998): Hepatitis C associated autoimmune disorders. Rheum. Dis. Clin. North Am., 24:353-74.

Mihai Olariu¹, Cristina Olariu², Dan Olteanu²(2010)
Thrombocytopenia in Chronic Hepatitis C ,University of Medicine and Pharmacy „Carol Davila” Bucharest,University Hospital Bucharest, RomaniaJ Gastrointestin Liver Dis, December 2010 Vol.19 No 4, 381-385

Missale G, B ertoni R, Lamonaca V, et al., (1996): Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.J clin. Invest. 98:706-714.

Mohammed Mk, Abdel-Hamid M, Mikhail NN, et al. (2005): Intrafamilial transmission of hepatitis C in Egypt. Hepatology, 42:683-687.

Mondelli, M.U. and Sillini, E. (2000): Clinical significance of HCV genotypes. *J. Hepatol.* 31: 65–70.

Mood, Alexander; Franklin A. Graybill, Duane C. Boes (1974).

Introduction to the Theory of Statistics (Third Edition, p. 241-246). McGraw-Hill.

Moreno A., Brcena R., Blzquez J., et al(2000). Thrombocytopenia can be found in patients with chronic hepatitis related to hepatitis C virus (HCV). Hospital Ramón y Cajal, Madrid, Spain. *N Engl J Med* 2000; 343:1673-1680.

Murphy, F.A.; C.M. Fraquet; D.H.L. Bishop; S.A. Ghabrial et al., (1995): Classification and nomenclature of viruses: sixth report of the internal committee on taxonomy of viruses. *P.* 424 – 426.

Nagamine T, Ohtuka T, Takehara K, et al (1996): Thrombocytopenia associated with hepatitis C viral infection. *J Hepatol* 1996;24:135-40.

Nagayoma R, Miyake K, Tsuda F, et al., (1994): IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of the disease. *J. Virol.*,68: 4420.

Narita R, Asaumi H, Abe S, et al(2003) : Idiopathic thrombocytopenic purpura with acute hepatitis C viral infection. *J Gastroenterol Hepatol* 2003;18(4):462-3.

Nathan, C. (1997): Inducible nitric oxide synthase; What difference does it make? *J. Clin. Invest.*, 100:2417-2423.

National Institutes of Health Consensus Development Conference (2002): Management of hepatitis C. *Gepatology*; 36(5 Suppl.1): S3-S13.

Ndjomou, J.; B. Kupfero; B. Kochan; L. et al (2002): HCV infection and genotypes among human immunodeficiency virus, high risk groups in Cameroon. J. Med. Virol 66: 179-186.

Neumann, A.U.; Lam, N.P. and Dahrari, G. (1998): Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon alpha therapy. Science; 282:103-7.

Nieswandt B and Waston SP(2003): Platelet collagen interaction: is GPVI the central receptor? Blood 2003;102:449-61.

Ning, Q; Brown, D. and parodo, J.(1996): Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves TH1 cytokine production but inhibits TH2 cytokine response. Hepatology; 24:355.

Nucci, M.L; Shorr, R. and Abuchowski, A.(1991); The therapeutic value of polyethylene glycol modified proteins. Adv. Drug Delivery Rev., 6:133-151.

Okada, S.I.; Akahance, Y.and Suzuki, H.(1992) The degree of variability in the amino terminal region of the E2/NSI protein of hepatitis C virus correlates with responsiveness to interferon therapy in viraemic patients. Hepatology; 16:619-24.

Olgle EF(2001): Clinical significance of thrombocytopenia in the adult patient. Physician Assistant 2001;25(2):18-26.

Orland, J.R.; Wright, T.L. and Cooper,S.(2001): Acute hepatitis C. Hepatology; 33:321-327.

Oxford, J.S. and Galbraith, A.(1980): Antiviral activity of amantadine : a review of laboratory and clinical data. Pharmacol. Ther., 11;181-262.

Panzer S and Seel E(2003): Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? (review). Wien Med Wochenschr 2003;153:417-20.

Papo, T.; Marcellin, P.; Bernuau, J.; et al (1992): Autoimmune chronic hepatitis exacerbated by alpha interferon. Ann. Intern. Med., 116:51-3.

Parolin, M.B.; Lacerda, M.A.and Loez, R.W.(1999): Amonatidine HCL in the treatment of CHC in non-responders to IFN. Arg. Gastroenterol., 36(2)63-7.

Patterson, J.B. and Samuel, C.E.(1995) Expression and regulation by interferon of a double stranded RNA specific adenosine deaminase from human cells is inducible by alpha and gamma interferons . Virology, 210:508-511.

Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al., (1995): Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 122:169-73.

Pawlotsky, J.M.; Pellet, C.; Udin, L. et al., (1995):Significance of anti- HCV core IgM antibodies in patients with chronic hepatitis C. J. Med. Virol. 47:285-291.

Peck- Radosavijevic M(2000): Thrombocytopenia in liver disease. Can J Gastroenterol. 2000;14(D):60-6.

Peck-Radosavljevic M, Wichlas M, Pidlich J, et al(1998): Blunted thrombocytopenia during treatment for hepatitis C. Hepatol 1998; 28:1424-9.

Peck-Radosavljevic M, Wichlas M, Pidlich J, et al(2000): thrombocytopenia induces rapid resolution of thrombocytopenia after

orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801.

Peerschke EI(2002): The laboratory evaluation of platelet dysfunction. Clin Lab Med 2002;22:405-20.

Perz JF and Alter MJ. (2006): The coming wave of HCV related liver disease. J. Hepatology, 44:441-443.

Pileri, P.; Uematsu, Y.; Campagnoli, S. et al., (1998): Binding of HCV to CD81. Science; 282: 938-941.

Pinzani M (2004): Pathogenesis of hepatic fibrosis (p. 121-129). In liver Disease from bench to bedside. American Association for the study of liver disease. Massachusetts, October 29-30.

Plaut D (2003): Platelet Function Tests. Advance for the Administrators of the Laboratory, July 2003.

Pockros PJ, Duchini A, McMillan R, et al (2002): Immune thrombocytopenia purpura in patients with hepatitis C virus infection. Am J Gastroenterol 2002;97:2040-5.

Poordad F(2007): Thrombocytopenia in chronic liver disease (Review article). Aliment pharmacol Ther 2007;26(1):5-11.

Poynard T, Imbert-Bismut F, Ratziu V and et al., (2002): Biochemical markers of liver fibrosis in patients infected by Hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat., 9:128-133.

Poynard T, Marcellin P, Lee SS, et al(1998): Randomised trial of interferon- α 2b plus ribavirin for 48 Weeks or for 24 Weeks versus interferon- α 2b plus placebo for 48 Weeks for the treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1425-32.

Provost N, Woulfe D, Tognolini M, et al(2003): Contact-dependent signaling during the late events of platelet activation. *J Thromb and Haemost* 2003;1:1613-27.

Ptossi, F.; Blank, A.; Schreder, A.; Hussi, P. et al .(1993): A functional GTP-binding motif is necessary for antiviral activity of MX proteins. *J. Virol.*, 67:6726-632.

Pybus, O.G.; M.A.Charleston; S.Gupta; et al (2001): The epidemic behavior of HCV. *Science* 292: 2323-2325.

Qamar AA, Grace ND, Groszmann RJ, et al(2009); Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. *Clin Gastroenterol Hepatol* 2009; 7: 689-695.

Rajan SK, Espina BM, Liebman HA,(2005) Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura, *Br J Haematol*, 2005;129:818–24.

Rand ML, Leung R and Packham MA(2003): Platelet function assays. *Transfus Apheresis Sci* 2003;28:307-17.

Ray R, Khanna A, Legging ML, et al., (1994): Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. *J. Hepatol.* 21 : 403-5.

Ray S., Arthur R. and Carella A. (2004): "Genetic epidemiology of hepatitis C virus throughout Egypt". *J. Infect. Dis.*; 182:698-707.

Ray S., Arthur R. and Carella A. (2004): "Genetic epidemiology of hepatitis C virus throughout Egypt". *J. Infect. Dis.*; 182:698-707.

Recanelli, V. and B. Rehermann (2003):HCV infection: when silence is deception.Trends Immunol 24: 456-464.

Reddy, K.R .;Wright, T.L.; Pockros, P.J.; et al (2001): Efficacy and safety of pegylated (40KD) interferon alpha-2a compares with interferon alpha-2a in non cirrhotic patients with chronic hepatitis C. Hepatology;33:433-438.

Reichard, O.; Giaumann, H.; Fryden, A.; et al (1999): Long term follow up of chronic hepatitis C patients with sustained virological response to alpha interferon. J.Hepatol., 30:783-7.

Reiser, M., C. Marousis, D. Nelson, G. et al. (1997):Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. *J Hepatol.* 26(3):471-8.

Renault PF, Hoofnagle JH(1989). Side effects of alpha interferon. Semin Liver Dis 1989; 9:273-277.

Renault, P.F.; Hoofnagle, J.H. and park, Y. (1987): Psychiatric complications of long term interferon alpha therapy. Arch. Intern. Med., 147:1577-80.

Rijnbrond, R.C.A. and S.M. Lemon (2000): Internal ribosome entry site- mediated translation in HCV replication, P.85-116. In C.Hagedorn and C.M. Rice (ed), Hepatitis C virus, vol. 242. Springer – Verlag, Berlin, Germany.

Rios R, SangroB, Herreo I,et al (2005): The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis Am J Gastroenterol 2005;100:1311-6

Robber b mayer MD, Mercedes DE, Francoise, et al :biochemical markers of fibrosis in patients with chronic hepatitis c virus.digestive disease and science, vol 48 pp 146-154.

Robert I. Handin, MD, Brigham & Women's Hospital(2005).

Inherited Platelet Disorders, Hematology Division 2005;02115-6110.

Roberts, R.M.; Liu, Guo, Q.: Leaman, D. and Bixby, J.(1998): The evolution of the type I interferons. J. Interferon Res., 18:805-816.

Robetorye R and Rodgers GM(2001) :Update on selected inherited thrombotic disorders .AM Jhematol 2001;68:256-68.

Rodgers GM(1999):Overview of platelet physiology and laboratory evaluation of platelet function.Clin Obstst Gynecol 1999;42:349-59.

Roomer R, Hansen BE, Janssen HL, de Knecht RJ.(2010)

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 2010; 53: 455-459.

Rossi, S.J. and Wright, T.L.(2003): New developments in the treatment of hepatitis C. Gut; 52: 756-757.

Rozmanp and Bolta Z(2007): Use of platelet growth factors in treating Wounds and soft tissue injuries
ActaDermatovenereolAlpPanonicaAdriat 2007;16:156-65.

Ruggeri ZM(2000): Role of von Willebrand factor in platelet thrombus formation. Ann Med 2000;32:2-9.

Ruggeri ZM(2002):Platelets in atherothrombosis. Nature Med2002;8:1227-34.

Sanchez-Quijano, A.; Andreu, j. and Gavilan, F. (1995): Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbil. Infect. Dis., 14949-53.

Sander S(2004): Immune thrombocytopenic purpura: An update for immunohematologists (Review article) *Immunohematol* 2004;20:112-7.

Saracco, G.; Rosina, and Abate, M.L. (1993): Long term follow up of patients with chronic hepatitis C treated with different doses of interferon α . *Hepatology*; 18:1300-5.

Schar RE and Aul C(1998): Alcohol-induced disorders of the hematopoietic system. *Z Gastroenterol* 1998;26(3):75-83.

Schervish MJ (1996). "P Values: What They Are and What They Are Not". *The American Statistician* 50 (3): 203–206.

Schiff E.R. (1997): "Hepatitis C and alcohol". *Hepatol*; 26(3 Suppl 1): 39S-42S.88.

Schinkel, J.; Spaan, W.J.; Kroes, A.C. (2004): Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. *Antivir Ther* 9:275-286.

Sekhon SS and Roy V(2006): Thrombocytopenia in Adults: A practical Approach to Evaluation and Management. *Southern Med J* 2006;99:491-8.

Sekkai D, et al(2007). Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. *Blood*. 2007;109:3225–3234.

Shaki, A.O.; McGuire, B.; Crippin, J.S.; et al (2000): Interferon-alfa 2b and ribavirin combination tgerapy in liver transplantation recipients with recurrent hepatitis C. *Hepatology*; 32:216A.

Shakil AO, Conry-Cantilena C, Alter HJ, et al. (1995): Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann. Intern. Med; 123: 330–7.

Sharma p , McDonald GB and Banaji M(1982): The risk of bleeding after percutaneous liver biopsy: Relation to platelet count. J Clin Gastroenterol 1982;4:451-11.

Sheila Sherlock and James Dooley (2002): Diseases of the liver and biliary system.

Shepard C.V., Finelli L., Fiore A.E. and Bell B.P. (2005): "Epidemiology of hepatitis B and hepatitis C virus infection in United States children". Pediatr. Infect. Dis. J.; 24: 755-760.

Shiffman ML, Ghany MG, Morgan TR, et al(2007). Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-112.

Shiffman, M.L.(2002): Retreatment of patients with chronic C. Hepatology; 36(5 Suppl.1):S128-34.

Shindo M, Arai K, Okuno Tet al (1997). The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J Hepatol. 1997 Mar;26(3):492-7.

Shindo M, Arai K, Sokawa Y, et al., (1995): The virological and histological states of anti-hepatitis C virus-positive subjects with normal. Ann Intern Med. 122:586-91.

Shirley A Coverdale , Dev A Samarasinghe , Rita Lin, et al(1998): Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic

Hepatitis C: Value for Predicting Fibrotic Progression, The American Journal of Gastroenterology 1998, 1384–1390

Silva M, Poo J, Wagner F, et al(2006). A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 45: 204-213, 2006.

Smith, P.J.(1997): Treatment of chronic hepatitis C with amantadine. Digest. Dis. Sci. vol. 42(8):1681-1687.

soza A,everhartJ.E,Ghany M.G,etal(2002) Neutropenia during combinationtherapyof interferon alfa andribavirin for chronichepatitis c.Hepatology,2002:36:1273-1279.

Staeheli, P.; Pitossi, F.and pavlovic, J. (1993): MX proteins: GTPases with antiviral activity. Trends Cell Biol., 3:268-272.

Stasi R, Sarpatwari A, Segal JB, et al(2009). Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. a systematic review. Blood 113: 1231-1240, 2009

Strader, D. B., & Seeff, L. B. (1996). The natural history of chronic hepatitis C, infection. European Journal of Gastroenterology & Hepatology, 8(4), 324-328.

Sulkowski M.S. and Thomas D.L. (2003): "Hepatitis C in the HIV-infected person". Ann. Intern. Med.; 138:197-200.

Sulkowski MS(2005): Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-16.

Sulkowski MS, Wasserman R, Brooks L. et al. Changes in haemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11:243-50

Takashi Himoto, Mikio Nishioka(2008) ;Autoantibodies in Hepatitis C Virus-Related Chronic Liver Disease,Hepatitis Monthly FALL 2008; 8(4): 295-303,

Tangiguchi, T. (1988): Regulation of cytokine gene expression. Annu. Rev. Immunol., 6:436-464.

Thompson S., Hernberger F., Wale E. and Crofts N. (2006): "Hepatitis C transmission through tattooing: a case report". Aust. N Z J Public Health; 20 (3): 317-8.

Tomikawa M, Hasizume M, Highashi H, et al(1996): The role of the spleen, platelets, and plasma hepatocytes growth factor activity on hepatic regeneration in rats. J Am Coll Surg 1996;182:12-6.

Tovey, M.G. (1988): The expression cytokines in the organs of normal individuals, in homeostasis. J.Biol.Rev. Hemostat. Agents ,2:87-92.

Tsiara S,ElisafM,JagroopIA and Mikhailidis DP(2003): Platelets as predictors of vascular risk : is there a practical index of platelet activity. ClinApp; Thromb Hemost 2003;177-90.

Tsukara A,Sato Y, Yamamoto S,et al(2003): Thrombopoietin levels and peripheral platelet counts following living related donor liver transplantation. Hepatogastroenterol 2003;50:227-30.

Vilcek, J. and DeMaeyer, E. (1984): Interferons and immune system. Elsevier Science Publishers, Amsterdam.

Voyer M., Nobre R. and Magny J.F. (2001): "Breast-feeding and hepatitis C virus (HCV): the need for a careful appraisal". Arch. Pediatr; 8(1): 66-77.

Wack KE, Ross MA, Zegarra V, et al: Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatol 2001;33:363-78.

Wang CS, Yao WJ, Wang ST, Chang TT and Chou P(2004): Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implication. Clin Infect Dis 2004; 39:790-6.

Wang CS, Yao WJ, Zegarra V, et al(2001): Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatol 2001; 33: 363-78.

Wang J.H., Changchien C.S. and Hung C.H. (2009): "Fibro Scan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis". J. Gastroenterol.; 44(5):439-46.

Wang Q, Miyakawa Y, Fox N, Kaushansky K(2009). Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96:2093–2099.

Wasley A. and Alter M.J. (2000): "Epidemiology of hepatitis C: geographic differences and temporal trends". Semin. Liver Dis.; 20:1-16.

Watson SP and Harrison P: The vascular function of platelets. Postgraduate Haematol 2005; 48:808-24.

Wedemeyer, H.; X.S. He; M. Mascimben, et al (2002):

Impairment effector function of HCV- specific CD8+ T cells in chronic HCV infection. J. Immunol. 169: 3447-3458.

Weitz IC(2005), Treatment of immune thrombocytopenia

associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 78: 138-141, 2005.

WHO (2000): Hepatitis C- global prevalence (update). Wkly

Epidemiol. Rec.; 75:18-9.

Williams, I. (1999): Epidemiology of hepatitis C in the United States.

Am. J. Med., 107(6B): 2S-9S.

Wong JB(2006). Hepatitis C: cost of illness and considerations for

the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-72.

Wong T, Lee SS (2006).Hepatitis C: a review for primary care

physicians. CMAJ 2006; 174: 649-59.

Wong, J.B.; Mcquillan, G.M.; McHutchison, J.G. et al. (2002):

Estimating future hepatitis C morbidity, mortality and costs in the united States. Am.J.Public Health; 1562-1569.

Wright, T.L.(2002); Treatment of patients with hepatitis C and

cirrrosis. Hepatology; 36(5 Suppl.1):S185-S194.

Yasushi Shiratori, MD; Fumio Imazeki, MD; Mitsuhiro

Moriyama, MD ET AL (2000); Histologic Improvement of Fibrosis

in Patients with Hepatitis C Who Have Sustained Response to

Interferon Therapy. Ann Intern Med April 4, 2000 132:517.

Yi, M. and S.M. Lemon (2003): 3' Nontranslatrd RNA signals

required for replication of HCV RNA. J. Virol 77: 3557-3568.

Zein, N.N. (2000):Clinical significance of HCV genotypes. Clin. Microbiol.Rev. 13: 223-235.

Zeki Karasu, Fatih Tekin, Galip Ersoz, et al 2007 : Liver Fibrosis Is Associated with Decreased Peripheral Platelet Count in Patients with Chronic Hepatitis B and C Digestive Diseases and Sciences.Volume 52, Number 6, 1535-1539

Zignego A.L., Ferri C., Caini P. and Bianchi F.B. (2006):
"For the Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C virus infection". Dig. Liver Dis.: p 23.

Zimmerman, Donald W. (1997). "A Note on Interpretation of the Paired-Samples t Test". Journal of Educational and Behavioral Statistics 22 (3): 349–360.